<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624052</url>
  </required_header>
  <id_info>
    <org_study_id>1235.8</org_study_id>
    <nct_id>NCT00624052</nct_id>
  </id_info>
  <brief_title>26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension</brief_title>
  <official_title>An Open Label Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 40mg + Amlodipine 10mg or Fixed Dose Combination of Telmisartan 80mg + Amlodipine 10mg Tablets Alone or in Combination With Other Antihypertensive Medications in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to assess the efficacy and safety of the fixed dose
      combinations telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg
      (T80/A10) during open-label treatment for at least six months.

      An additional objective is to assess the efficacy and safety of concomitant administration of
      either T40/A10 or T80/A10 with any other therapies commonly used in the treatment of
      hypertension.

      The primary endpoint is the proportion of patients achieving DBP control (defined as mean
      seated DBP &lt; 90 mmHg at trough i.e. approximately 24 hours after last dose of study
      treatment) at six months of treatment or at last trough observation during the treatment
      period (i.e. last trough observation carried forward).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Seated Diastolic Blood Pressure (DBP) Control</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reached the target DBP of &lt;90mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Seated Systolic Blood Pressure (SBP) Control</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reached the target SBP of &gt;=140mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure</measure>
    <time_frame>Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment</time_frame>
    <description>Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052</measure>
    <time_frame>Last available trough in NCT00553267 to end of study (34 weeks or last value on treatment)</time_frame>
    <description>The difference between the last available troughs represents the additional reduction in DBP in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure</measure>
    <time_frame>Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment</time_frame>
    <description>Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052</measure>
    <time_frame>Last available trough in NCT00624052 to end of study (34 weeks or last value on treatment)</time_frame>
    <description>The difference between the last available troughs represents the additional reduction in SBP in this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated DBP Response</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated SBP Response</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough BP Normality Classes</measure>
    <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach predefined BP categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Additional Antihypertensive</measure>
    <time_frame>up to 34 weeks</time_frame>
    <description>Time from first intake of medication to first intake of an antihypertensive other than the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control</measure>
    <time_frame>up to 34 weeks</time_frame>
    <description>The number of patients with DBP control (DBP&gt;=90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Reduction in DBP by Use of Additional Antihypertensive Therapy</measure>
    <time_frame>up to 34 weeks</time_frame>
    <description>Difference in trough DBP from last visit before add-on therapy and last visit during NCT00624052</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Reduction in SBP by Use of Additional Antihypertensive Therapy</measure>
    <time_frame>up to 34 weeks</time_frame>
    <description>Difference in trough SBP from last visit before add-on therapy and last visit during NCT00624052</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough DBP Control Pre- and Post- Uptitration</measure>
    <time_frame>up to 34 weeks</time_frame>
    <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before uptitration to telmisartan 80mg and amlodipine 10mg compared to first trough DBP taken after uptitration. Uptitration could be based DBP&gt;90 or investigator opinion.</description>
  </secondary_outcome>
  <enrollment type="Actual">838</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fixed-dose combination of telmisartan 40mg+amlodipine 10mg</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fixed-dose combination of telmisartan 80mg+amlodipine10mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - diagnosis of essential hypertension

        Exclusion Criteria:

          -  pregnancy, breast-feeding, unwilling to use effective contraception (if female of
             child-bearing potential).

          -  development of any condition in the preceding trial that could be worsened by
             telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg
             (T80/A10).

          -  discontinuation from the preceding trial.

          -  known or suspected secondary hypertension.

          -  mean seated systolic blood pressure (SBP) &gt;= 180 mmHg and/or mean seated diastolic
             blood pressure (DBP) &gt;= 120 mmHg at any visit.

          -  any clinically significant hepatic impairment or severe renal impairment bilateral
             renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal
             transplant.

          -  clinically relevant hyperkalaemia.

          -  uncorrected volume or sodium depletion.

          -  primary aldosteronism.

          -  hereditary fructose or lactose intolerance.

          -  symptomatic congestive heart failure.

          -  patients who have previously experienced symptoms characteristic of angioedema during
             treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor
             blockers (ARBs).

          -  any new drug or alcohol dependency since signing consent of the preceding trial.

          -  concurrent participation in another clinical trial or any investigational therapy
             since completing the preceding trial.

          -  hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the
             aortic or mitral valve.

          -  known allergic hypersensitivity to any component of the formulations under
             investigation. [Includes known hypersensitivity to telmisartan or other ARBs or
             amlodipine or other dihydropyridine calcium channel blockers (CCBs).] non-compliance
             with study medication (defined as &lt;80% or &gt;120%) during the preceding trial.

          -  administration of ARBs or dihydropyridine CCBs (apart from trial medication). any
             other clinical condition which, in the opinion of the investigator, would not allow
             safe completion of the protocol and safe administration of telmisartan and amlodipine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.8.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kippa-Ring</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.61005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.43007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eggenburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hainburg a.d. Donau</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35912 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35907 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35910 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35911 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Benatky nad Jizerou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pribram</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strakonice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birr</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carrigtowhill</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gorey, Co. Wexford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mallow</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.35301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Ross</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Broni (pv)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coppito (AQ)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.64003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.64002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Otahuhu, Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.64001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.70012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dolny Kubin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kralovsky Chmlec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trencin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.42107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vrable</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jerez de la Frontera (Cádiz)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lvov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.38007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bexhill on Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burbage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chestfield, Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chorley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ely</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fowey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Penzance</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Austell</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.8.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <results_first_submitted>December 28, 2009</results_first_submitted>
  <results_first_submitted_qc>February 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2010</results_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan 40mg and Amlodipine 10mg</title>
          <description>Patients who were randomised to telmisartan 40mg and amlodipine 10mg and were on this dose at their last study visit</description>
        </group>
        <group group_id="P2">
          <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          <description>Patients who were randomised to telmisartan 80mg and amlodipine 10mg and were on this dose at their last study visit</description>
        </group>
        <group group_id="P3">
          <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          <description>Patients who were randomised to telmisartan 40mg and amlodipine 10mg but were titrated to telmisartan 80mg and amlodipine 10mg and were on this dose at their last study visit</description>
        </group>
        <group group_id="P4">
          <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          <description>Patients who were on either telmisartan 40 mg or 80mg and amlodipine 10mg plus another antihypertensive medication at their last study visit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="436"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="422"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with the protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Changed job/ran out if meds</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan 40mg and Amlodipine 10mg</title>
        </group>
        <group group_id="B2">
          <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
        </group>
        <group group_id="B3">
          <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
        </group>
        <group group_id="B4">
          <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="219"/>
            <count group_id="B2" value="436"/>
            <count group_id="B3" value="91"/>
            <count group_id="B4" value="92"/>
            <count group_id="B5" value="838"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="9.9"/>
                    <measurement group_id="B2" value="57.3" spread="9.4"/>
                    <measurement group_id="B3" value="55.2" spread="9.7"/>
                    <measurement group_id="B4" value="53.3" spread="10.3"/>
                    <measurement group_id="B5" value="56.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Seated Diastolic Blood Pressure (DBP) Control</title>
        <description>The number of patients who reached the target DBP of &lt;90mmHg</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated Diastolic Blood Pressure (DBP) Control</title>
          <description>The number of patients who reached the target DBP of &lt;90mmHg</description>
          <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (DBP&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="402"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (DBP&gt;=90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated Systolic Blood Pressure (SBP) Control</title>
        <description>The number of patients who reached the target SBP of &gt;=140mmHg</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated Systolic Blood Pressure (SBP) Control</title>
          <description>The number of patients who reached the target SBP of &gt;=140mmHg</description>
          <population>The full analysis set of patients. All patients who took at least one dose of study medication and have at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (SBP&lt;140 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="366"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (SBP&gt;=140 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure</title>
        <description>Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.6</description>
        <time_frame>Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment</time_frame>
        <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 NCT00553267) and at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure</title>
          <description>Change from baseline to the end of study in trough DBP. Baseline is defined as visit 3 of trial 1235.6</description>
          <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 NCT00553267) and at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.41" spread="0.44"/>
                    <measurement group_id="O2" value="-13.36" spread="0.31"/>
                    <measurement group_id="O3" value="-11.52" spread="0.69"/>
                    <measurement group_id="O4" value="-10.64" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052</title>
        <description>The difference between the last available troughs represents the additional reduction in DBP in this study</description>
        <time_frame>Last available trough in NCT00553267 to end of study (34 weeks or last value on treatment)</time_frame>
        <population>All patients who took at least one dose of study medication, have a trough end of study measurement from NCT00553267 and at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052</title>
          <description>The difference between the last available troughs represents the additional reduction in DBP in this study</description>
          <population>All patients who took at least one dose of study medication, have a trough end of study measurement from NCT00553267 and at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="430"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.36" spread="0.48"/>
                    <measurement group_id="O2" value="-4.97" spread="0.34"/>
                    <measurement group_id="O3" value="-5.51" spread="0.74"/>
                    <measurement group_id="O4" value="-5.43" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure</title>
        <description>Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.6</description>
        <time_frame>Baseline is defined as visit 3 of study NCT00553267 and end of study as 34 weeks or last value on treatment</time_frame>
        <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 NCT00553267) and at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure</title>
          <description>Change from baseline to the end of study in trough SBP. Baseline is defined as visit 3 of trial 1235.6</description>
          <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 NCT00553267) and at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.76" spread="0.72"/>
                    <measurement group_id="O2" value="-15.93" spread="0.5"/>
                    <measurement group_id="O3" value="-14.85" spread="1.12"/>
                    <measurement group_id="O4" value="-12.44" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052</title>
        <description>The difference between the last available troughs represents the additional reduction in SBP in this study</description>
        <time_frame>Last available trough in NCT00624052 to end of study (34 weeks or last value on treatment)</time_frame>
        <population>All patients who took at least one dose of study medication, have a trough end of study measurement from NCT00553267 and at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052</title>
          <description>The difference between the last available troughs represents the additional reduction in SBP in this study</description>
          <population>All patients who took at least one dose of study medication, have a trough end of study measurement from NCT00553267 and at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="430"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.73" spread="0.73"/>
                    <measurement group_id="O2" value="-6.02" spread="0.51"/>
                    <measurement group_id="O3" value="-6.55" spread="1.11"/>
                    <measurement group_id="O4" value="-5.61" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated DBP Response</title>
        <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 NCT 00553267) and at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated DBP Response</title>
          <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
          <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 NCT 00553267) and at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201"/>
                    <measurement group_id="O2" value="405"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated SBP Response</title>
        <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 NCT 00553267) and at least one on treatment BP measurement 20-30 hours post dose</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated SBP Response</title>
          <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
          <population>All patients who took at least one dose of study medication, have a trough baseline measurement (Visit 3 NCT 00553267) and at least one on treatment BP measurement 20-30 hours post dose</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="401"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough BP Normality Classes</title>
        <description>The number of patients who reach predefined BP categories</description>
        <time_frame>End of study (34 weeks or last value on treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O2">
            <title>Randomised Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Titrated Telmisartan 80mg and Amlodipine 10mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on</title>
          </group>
        </group_list>
        <measure>
          <title>Trough BP Normality Classes</title>
          <description>The number of patients who reach predefined BP categories</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="430"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal (SBP&lt;120 and DBP&lt;80 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (SBP&lt;130 and DBP&lt;85 mmHg and not optimal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="146"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-normal (SBP&lt;140 DBP&lt;90 mmHg and not normal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 1 hypertension (SBP&lt;160 and DBP&lt;100 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2 hypertension (SBP&gt;=160 and DBP&gt;=100 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Additional Antihypertensive</title>
        <description>Time from first intake of medication to first intake of an antihypertensive other than the study drug</description>
        <time_frame>up to 34 weeks</time_frame>
        <population>The total of the number of patients in the BP normality classes. Decision to treat with additional antihypertensive was at investigator discretion. Some patients may have been deemed to be at higher cardiovascular risk therefore requiring additional antihypertensive treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Time to First Additional Antihypertensive</title>
          <description>Time from first intake of medication to first intake of an antihypertensive other than the study drug</description>
          <population>The total of the number of patients in the BP normality classes. Decision to treat with additional antihypertensive was at investigator discretion. Some patients may have been deemed to be at higher cardiovascular risk therefore requiring additional antihypertensive treatment</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control</title>
        <description>The number of patients with DBP control (DBP&gt;=90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment</description>
        <time_frame>up to 34 weeks</time_frame>
        <population>Decision to treat with additional antihypertensive was at investigator discretion. Some patients may have been deemed to be at higher cardiovascular risk therefore requiring additional antihypertensive treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-antihypertensive: Yes (DBP&lt;90 mmHg)</title>
          </group>
          <group group_id="O2">
            <title>Pre-antihypertensive: No (DBP&gt;=90 mmHg)</title>
          </group>
          <group group_id="O3">
            <title>Pre-antihypertensive: Total</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Additional Antihypertensive Therapy to Achieve DBP Control</title>
          <description>The number of patients with DBP control (DBP&gt;=90 mmHg). Last trough DBP measurement before taking additional antihypertensive compared to last trough DBP taken on treatment</description>
          <population>Decision to treat with additional antihypertensive was at investigator discretion. Some patients may have been deemed to be at higher cardiovascular risk therefore requiring additional antihypertensive treatment</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-antihypertensive: Yes (DBP&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-antihypertensive: No (DBP&gt;=90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-antihypertensive: Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Reduction in DBP by Use of Additional Antihypertensive Therapy</title>
        <description>Difference in trough DBP from last visit before add-on therapy and last visit during NCT00624052</description>
        <time_frame>up to 34 weeks</time_frame>
        <population>Total for the full analysis set. Decision to treat with additional antihypertensive was at investigator discretion. Some patients may have been deemed to be at higher cardiovascular risk therefore requiring additional antihypertensive treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Additional Reduction in DBP by Use of Additional Antihypertensive Therapy</title>
          <description>Difference in trough DBP from last visit before add-on therapy and last visit during NCT00624052</description>
          <population>Total for the full analysis set. Decision to treat with additional antihypertensive was at investigator discretion. Some patients may have been deemed to be at higher cardiovascular risk therefore requiring additional antihypertensive treatment</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.79" spread="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Reduction in SBP by Use of Additional Antihypertensive Therapy</title>
        <description>Difference in trough SBP from last visit before add-on therapy and last visit during NCT00624052</description>
        <time_frame>up to 34 weeks</time_frame>
        <population>Total for the full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40mg and Amlodipine 10mg</title>
          </group>
        </group_list>
        <measure>
          <title>Additional Reduction in SBP by Use of Additional Antihypertensive Therapy</title>
          <description>Difference in trough SBP from last visit before add-on therapy and last visit during NCT00624052</description>
          <population>Total for the full analysis set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.79" spread="12.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough DBP Control Pre- and Post- Uptitration</title>
        <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before uptitration to telmisartan 80mg and amlodipine 10mg compared to first trough DBP taken after uptitration. Uptitration could be based DBP&gt;90 or investigator opinion.</description>
        <time_frame>up to 34 weeks</time_frame>
        <population>91 is the number of patients titrated to telmisartan 80mg. To get 582 you need to consider the randomised to telmisartan 80 mg patients and those with additional antihypertensive that were on telmisartan 80mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-titration: Yes (DBP&lt;90 mmHg)</title>
          </group>
          <group group_id="O2">
            <title>Pre-titration: No (DBP&gt;=90 mmHg)</title>
          </group>
          <group group_id="O3">
            <title>Pre-titration: Total</title>
          </group>
        </group_list>
        <measure>
          <title>Trough DBP Control Pre- and Post- Uptitration</title>
          <description>The number of patients with DBP control (DBP&lt;90 mmHg). Last trough DBP measurement before uptitration to telmisartan 80mg and amlodipine 10mg compared to first trough DBP taken after uptitration. Uptitration could be based DBP&gt;90 or investigator opinion.</description>
          <population>91 is the number of patients titrated to telmisartan 80mg. To get 582 you need to consider the randomised to telmisartan 80 mg patients and those with additional antihypertensive that were on telmisartan 80mg.</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="258"/>
                <count group_id="O3" value="582"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-titration: Yes (DBP&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                    <measurement group_id="O2" value="168"/>
                    <measurement group_id="O3" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-titration: No (DBP&gt;=90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-titration: Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="258"/>
                    <measurement group_id="O3" value="582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day of first dose through to the day after last dose</time_frame>
      <desc>Safety data was analysed based upon actual dose of telmisartan and amlodipine the patient was on at the onset of AE regardless of additional antihypertensive</desc>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 40mg and Amlodipine 10mg</title>
          <description>The 838 participants in the telmisartan 40mg/amlodipine 10mg group includes all participants</description>
        </group>
        <group group_id="E2">
          <title>Telmisartan 80mg and Amlodipine 10mg</title>
          <description>The 611 participants in the telmisartan 80mg/amlodipine 10mg (T80/A10) group include 436 patients in the randomised T80/A10 group + 91 patients in the uptitrated T80/A10 group + XX patients in the T80/A10 + add-on group</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Stent related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Postoperative fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Fibrosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Parasoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="611"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="838"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="611"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

